GNS Healthcare Names Dr. David Sontag to its Strategic Advisory Board

By |

CAMBRIDGE, Mass. – November 8, 2017– Leading precision medicine company GNS Healthcare (GNS) today announced the appointment of Dr. David Sontag to its Strategic Advisory Board (SAB). Dr. Sontag’s research interests include machine learning and artificial intelligence with a focus on unsupervised learning and causal inference. “David’s expertise in artificial intelligence and machine learning will…

Read More

AI-Driven Discovery of Novel Predictors of Parkinson’s Disease Progression by GNS Healthcare Appears in The Lancet Neurology

By |

Discovery May Accelerate the Development of New Drugs & Better Match New Drugs to Individual Patients CAMBRIDGE, Mass.– Sept 26, 2017 – GNS Healthcare (GNS), a leading precision medicine company, announced today the discovery of genetic and molecular markers of faster motor progression of Parkinson’s Disease (PD) patients, the LINGO2 gene…

Read More

GNS Healthcare and Swedish Cancer Institute Launch Machine Learning Collaboration to Strengthen Delivery of Precision Medicine in Breast Cancer Care

By |

Causal Computer Models to Accelerate Work of Swedish Cancer Institute’s Molecular Tumor Board CAMBRIDGE, Mass. and SEATTLE, Sept. 13, 2017 /PRNewswire/ — Leading precision medicine company GNS Healthcare (GNS) and the Swedish Cancer Institute (SCI) today announced a machine learning collaboration to strengthen, accelerate, and potentially expand the delivery of precision medicine in breast cancer care. GNS will employ its breakthrough…

Read More